Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But if that were the case it would have tumbled back. They would have taken profits. Traders take profits they don't invest long term. Something else is up. If it was just traders this would have cratered back and fell negative on profit taking. Why would they hold? It is something else going on behind the scenes.
The high volume started the other day so you are wrong.
Two days before Inovio Pharmaceuticals had announced its partnership with Roche it saw its stock go up 30% two days in a row with big volume. Despite SEC rules there always is a leak somewhere.
Gotta be a leak about something going on. Another thing I think it could be is a big pharmaceutical buying a 20% stake in RXII little by little. For instance Sanofi has acquired a sizeable stake in Alnylam. Could it be that a big pharma company is buying a 20% stake in RXII. Then it could also partner on a program like cosmecueitcals as well. The reason they probably haven't announced anything yet is because they want to buy up the shares first but at a moderate rate.
What impressive from the slide is that a majority of the patients in the 70 weeks extension study have a TND -- target not detected. That means their HIV viral copy level is so low blood tests aren't even detecting it in the body. Amazing results for CYDY
Yep News. ASM Microbe 2016 Presentation of Clinical Results From CytoDyn’s Phase 2b Monotherapy Extension Study Now Available
http://content.stockpr.com/cytodyn/files/docs/ASM+Microbe+Conference+Presentation+by+Dr.+Paul+J.+Maddon+re+PRO+140_June+20+2016_Boston.pdf
The volume today was 10x normal average volume. Something is up IMO. If volume continues tomorrow again, then I know something is coming down the pipe. Unless they reveal news tomorrow morning.
I read that too and laughed. First of all what patients want to take pills everyday for the rest of their lives?
Given the choice of one weekly self injection or pills everyday patients would more than likely choose the once a week injection.
As many have mentioned the current pill treatments have headaches, nausea, vomiting, liver damage, kidney damage. Cytodyn Pro 140 has none of those, so patients would be better off with Pro 140.
But as you mention if that Doctor has a relationship of some sort with Gilead sciences then it is bias as Gilead stands to lose billions of dollars.
They have to wait till after the presentation. Why do people never read?
$2 is enough to uplist, but only on the NYSE. NYSE only requires $2 for initial uplist. NASDAQ requires $4 or $5 initially.
Of course though going on the NYSE would be good enough anyways as institutions could buy in.
April of 2011. To date all the patients treated with Pro 140 have shown no side effects since the trials have started. That article is old and clearly because no patient has developed this after 5 or 6 years of treatment this has been debunked. Nice try, but try harder next time.
Rxi Pharmaceuticals (RXII) Research Report 2016
https://groups.google.com/forum/#!topic/helios-biotech-research/hzmOOrOe1Rc
A Cytodyn (CYDY) Research Report I wrote for 2016
https://groups.google.com/forum/#!topic/helios-biotech-research/rvWj0QUs2xM
You wanna know my reason? Gilead sciences stands to lose 44% of its HIV revenue. The question is not if CYDY will get bought out? But when will CYDY get bought out?
Well also maybe for the fact that the ASM microbiome conference is coming up on Monday.
I agree no harm in taking a profit but why would you? The conference is coming on Monday, stock could potentially spike higher.
Nowhere to go but up from here!
I looked a the presentation on the website and noticed though that Galmed isn't targeting stage 3 and stage 4 fibirosis. They are only at the moment targeting stage 1, stage 2, like Intercept and Genfit.
Only Gilead and GALT are targeting stage 3 and stage 4 -- advanced fibrosis.
I don't know where to begin with that statement. I mean lets so hypothetically you were an HIV patient.
Would you rather take pills everyday the rest of your life with toxic side effects like nausea, vomiting, upset stomatch, liver damage, kidney damage etc.
or, would you rather take a one week self injectable drug with no side effects?
I know right now if I had HIV I would choose the injection. What HIV patients wants to live everyday with Nausea, vomiting and liver damage? Would you enjoy going through everyday of your life with nausea? I guess some would....... anyways
Self injections are the future. I don't know why DoctorRX answered the way he did. how is there not a lot of potential? If adequate don't you think doctors would want to switch their patients away from taking pills everyday to a one-week injectable drug? I would think so.
Of course but as you say its not illegal. He can come on to twitter saying those things with no legal action can be taken against him? Why? Because he is not telling anyone to buy the stock.
If he comes out on twitter and says "Buy AMBS because its a great company" he can't do that.
By saying he "the ceo" would be buying all day is not illegal. He is saying what he would do.
There are loopholes to laws and as you can see they are using them. What he is doing is legal. the CEO is careful not to break the law.
For example The CEO saying "going from 0 to 100 real fast" is a pump and shady but not illegal because he is not telling anyone to buy shares of AMBS.
Anyways the only legal action is if someone can prove that they directly benefited from using toxic financing. Claiming for salary is no good, they will just point to the fact they were raising money for trials. There is always a loophole to everything.
As much as I think AMBS is a scam their is nothing that attorney can do for that lady. In order to win in court you have to prove that the board and CEO acted maliciously. That means a plaintiff must hold in their hands proof of that.
The problem with these biotechnology companies is that they always hide behind safe harbor statements and forward looking statements. That's what protects them. In those statements they tell you up front that the investment is risky and you may lose everything.
That's not to say those companies can't be sued if the directors acted in a malicious manner, it's just that you have to prove in court with actual evidence. If you don't have that well you are out of luck.
But I agree with you JP this company is a scam outfit, to take people's money and earn yearly salary. The problem is that you have to prove it to the SEC and in court.
$5 billion is doable yes. Even though the drug is not out yet it commands a large market. Cytodyn Pro 140 targets a $15 billion market.
I can give you good examples.
Roche bought Intermune for $8.3B. yes the drug was already approved but at that time only in Europe. U.S. approval wasn't coming month later until November.
There are other examples I just can't think of them. Anyways in this case though Cytodyn is going to eat into Gilead's HIV revenue. It would be prudent and smart for Gilead to acquire the company before they reach approval, and before the drug is marketed. I mean they could wait but they would have to pay a higher premium. Either way I will await that day because I know its coming.
But Taimeds drug is only given through the hospital setting intravenously. In other words the patient has to travel to the hospital every time they need treatment and then wait a few hours to be given an IV line, and then wait 30 mins until all said IV treatment is done. Taimeds drug is an IV drug not an injection.
IV drugs take time to deplete if anyone has ever seen cancer patients receive IV chemo. Yes Taimed may be approved first but CYDY will have the upper hand with home self injection care. Please stop rehashing Taimed.
People we are sitting on a goldmine here, Very rare that a company in two phase 3 clinical trials that target a $15 billion market is sitting so low. Gilead will protect its 44% yearly HIV revenue, start loading the boat CYDY and retire happy IMO.
Nope. If this was traded on the NASDAQ it would already be at $20 to $30 per share at least
I think you are right about dilution if it comes to that, but a partnership would bring upfront money. In that scenario the company won't have to dilute. Like I have said this is all dependent upon a multitude of factors. We shall find out soon enough. GL to all, I have been adding and will continue to add if the share price remains under $2 to $3 dollars.
Yep and that's just in the U.S. market. That doesn't include the other parts of the world. Which leads me to believe a potential partnership could come in the form of an international partner, while CYDY targets the U.s. market.
He didn't say, The CEO just said they are not allowed to talk about partnerships and kept it at that.
Anyone else catch the previous conference call and the question at this presentation about partnerships?
When other biotech company CEOs get asked this question they will say we are talking with partners, we are in discussion with a few.
But both times when the CEO of Cytodyn was asked about partnership questions, he completely avoided them citing NDA. I know it's not good to read too much into things, but do you think the CEO is keeping hush hush on a possible partnership?
I have never seen a CEO that cite Non-disclosure agreement when asked about partnerships. Most other biotech cEO's I have seen pump it up. Saying we are in active talks with potential partners etc. That leads me to believe something is in the works.
I actually caught that. It says "with this new ESS supply we will initiate the trial in the near future". You are spot on, they don't give a date or time period of when it will start.
Yes CYDY's prospects are strong but I'm betting big on this, because I believe if the efficacy data on June 20th is good, then I have a strong feeling Gilead Sciences will buy it out. It is not my belief that Gilead sciences will stand by and watch 44% of their HIV revenue diminish into nothing.
OTC is heavily shorted. Plus no buying pressure from institutions. Only retail investors, so its a tough place to be.
Does that mean that AMBS will default tonight if it doesn't file anything? if so I feel bad for all those shareholders that bought shares here.
Sadly Josh Sason owns the company now, and the will continue the reverse split and dilution game forever now. Shareholders will never make money, but Josh Sason and GC will always be rich so its a win in their eyes.
Do well? LOL. It hasn't even started to recruit patients in a clinical trial....
Thank you 5STOP I totally agree with u. Plus this is detailed data, we will find out how much viral loads are being stopped, how many days viral loads are stopped in, etc. If the results are far superior to Gliead's drugs -- standard of care -- then I believe it will move the share price.
All the company has released thus far is that patients have been off of ART therapy for 17 months or more. But they haven't given detail on viral loads or any other data.
All they have said is that patients continue viral supression for 17 months or more. There has been no detailed data released. We don't know the patient's viral loads, viral copies in the body, how many days viral copies are supressed etc.
Sorry but I think that you are totally wrong in this regards. All the company has released thus for for phase 2b monotherapy is that patients have been off of ART therapy with Pro 140 for 14 months or more. No detailed data has been released. I believe with good data the stock will react accordingly.
No I think they want to see how the price will react first after the phase 2b monotherpay results and subsequent press coverage. It could ignite the stock all the way past $2 per share.
If on the other hand the phase 2b monotherapy results, and press coverage doesn't deliver along with other news they will probably eventually opt for an uplist to the NYSE probably.
Yes but patients will still have to take Gilead's drugs everyday. PRO 140 is going to be administered once a week as a self injection. In addition, with further testing the company also wants to test it out to one injection every 2 weeks because PRO 140 is long acting. Therefore they can stretch treatment out possible to 2 weeks or more. Think about having to take 2 to 4 injections per month compared to one pill everyday for 30 days a month. There is just no comparison.
I'm sticking to my gut feeling that Gilead Sciences is in the works of making offers or talking to management of CYDY. That's all IMO. But I feel that for the right price management might sell. If anything this company will get bought out by a big pharma. So win/win. Either it gets to approval and starts marketing the drug, or it gets bought out. Either way shareholders win.